Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis

  • The PLOS ONE Staff

There is an error in the seventh sentence of the abstract. The correct sentence is: From 2005–2009 to 2015–2019, the median monthly product price over all distinct indications of all products decreased by 7.56% (CHF 5,699 [interquartile range 4,483–7,321] to CHF 5,268 [4,019–6,967]), whereas it increased by 73.7% for monoclonal antibodies.

The ORCID iD is missing for the second author. Author Christoph Jakob Ackermann’s ORCID iD is: 0000-0003-2621-5512 (https://orcid.org/0000-0003-2621-5512).

The publisher apologizes for the errors.

Reference

  1. 1. Rachamin Y, Ackermann CJ, Senn O, Grischott T (2021) Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis. PLoS ONE 16(11): e0259936. pmid:34780556

Citation: The PLOS ONE Staff (2022) Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis. PLoS ONE 17(2): e0264610. https://doi.org/10.1371/journal.pone.0264610

Published: February 23, 2022

Copyright: © 2022 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.